Axial Therapeutics (Woburn, MA), a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases, today announced the completion of a $37.25 million Series C financing. OneVentures, a venture capital firm headquartered in Sydney, Australia, and UTokyo Innovation Platform Co., Ltd. (UTokyo IPC) led the round as new investors, joined by Autism Impact Fund and Corundum Systems Biology. Existing investors, Longwood Fund, Seventure Partners, Taiho Ventures, and Domain Associates also participated in this round. Professors Satoshi Uematsu and Seiya Imoto at The Institute of Medical Science, The University of Tokyo, serve as Scientific Advisory Board members for the company. In connection with the financing, Sarah Meibusch, principal, OneVentures, and Makoto (Mark) Ohori, Ph.D., Partner, Chief Investment Officer, Life Science at UTokyo IPC have joined Axial’s board of directors.